Relay Therapeutics (RLAY) Accumulated Depreciation (2019 - 2023)

Relay Therapeutics (RLAY) has 5 years of Accumulated Depreciation data on file, last reported at $23.6 million in Q4 2023.

• Quarterly Accumulated Depreciation rose 28.24% year-over-year to $23.6 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $23.6 million (up 28.24% YoY) and the FY2023 annual result came in at $23.6 million, up 28.24% from the prior year.
• Accumulated Depreciation advanced to $23.6 million in Q4 2023 per RLAY's latest filing, from $18.4 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $23.6 million in Q4 2023 and bottomed at $7.0 million in Q4 2019.
• The 5-year median for Accumulated Depreciation is $14.4 million (2021), against an average of $14.8 million.
• The widest annual swing landed in 2020, when Accumulated Depreciation surged 50.84%; it then rose 27.99% in 2022.
• Tracing RLAY's Accumulated Depreciation over 5 years: stood at $7.0 million in 2019, then soared by 50.84% to $10.5 million in 2020, then jumped by 36.44% to $14.4 million in 2021, then climbed by 27.99% to $18.4 million in 2022, then increased by 28.24% to $23.6 million in 2023.
• Per Business Quant, the three latest RLAY Accumulated Depreciation figures stand at $23.6 million (Q4 2023), $18.4 million (Q4 2022), and $14.4 million (Q4 2021).

Peer Comparison